Kijima Toshiki, Fujii Yasuhisa, Suyama Taisuke, Okubo Yuhei, Yonese Junji, Fukui Iwao
Department of Urology, Cancer Institute Hospital, Japanese Foundation of Cancer Research, Tokyo, Japan.
Int J Urol. 2008 Jun;15(6):546-7. doi: 10.1111/j.1442-2042.2008.02044.x.
Bisphosphonates (BP) are inhibitors of bone-resorption and have become the current standard of care for preventing skeletal complications associated with bone metastases. Although previous reports have also suggested potent antitumor, antiangiogenic and immunomodulatory properties of BP, there is debate about the clinical relevance of experimental in vitro and in vivo findings. We report a renal cell carcinoma case in which multiple lung and bone metastases displayed remarkable remission to BP therapy using 30 mg pamidronate once, 4 mg zoledronate once, and weekly 10 mg incadronate 10 times for 3 months. This is the first case report to demonstrate that BP therapy is effective to non-osseous visceral metastasis as well as bone metastases in the clinical setting.
双膦酸盐（BP）是骨吸收抑制剂，已成为预防与骨转移相关的骨骼并发症的当前标准治疗方法。尽管先前的报告也表明BP具有强大的抗肿瘤、抗血管生成和免疫调节特性，但关于体外和体内实验结果的临床相关性仍存在争议。我们报告了一例肾细胞癌病例，该病例有多发性肺和骨转移，使用30 mg帕米膦酸一次、4 mg唑来膦酸一次以及每周10 mg因卡膦酸10次，共3个月，对BP治疗表现出显著缓解。这是首例证明BP治疗在临床环境中对非骨性内脏转移以及骨转移均有效的病例报告。
